{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:41Z","timestamp":1792839701466,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jhep.2016.10.017","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T18:35:28Z","timestamp":1477161328000},"page":"485-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":244,"title":["Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"],"prefix":"10.1016","volume":"66","author":[{"given":"Adriaan J.","family":"van der Meer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero L.","family":"Almasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Calvaruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado M.","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Ganne-Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Trapero-Marugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoel","family":"Maan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Moreno-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"de Knegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.10.017_b0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.10.017_b0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.10.017_b0015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.10.017_b0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.10.017_b0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.10.017_b0035","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0149-2918(11)00022-1","article-title":"A review of the treatment of chronic hepatitis C virus infection in cirrhosis","volume":"32","author":"Vezali","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2016.10.017_b0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/jvh.12249","article-title":"Strategies to manage hepatitis C virus (HCV) disease burden","volume":"21","author":"Wedemeyer","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.10.017_b0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","article-title":"Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0050","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","article-title":"Hepatitis C virus testing of persons born during 1945\u20131965: recommendations from the Centers for Disease Control and Prevention","volume":"157","author":"Smith","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.017_b0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.10.017_b0070","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/ajg.2010.294","article-title":"Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response","volume":"105","author":"Fernandez-Rodriguez","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.017_b0075","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.10.017_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1757-1626-2-18","article-title":"Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report","volume":"2","author":"Mashitani","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.jhep.2016.10.017_b0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350901400415","article-title":"The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype","volume":"14","author":"Aghemo","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.10.017_b0090","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.3748\/wjg.v13.i42.5648","article-title":"Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin","volume":"13","author":"Braks","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.017_b0095","first-page":"253A","article-title":"Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV","volume":"56","author":"Calvaruso","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0100","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2009.08.071","article-title":"Randomized study of peginterferon-alpha2a plus ribavirin vs. peginterferon-alpha2b plus ribavirin in chronic hepatitis C","volume":"138","author":"Rumi","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.10.017_b0115","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1016\/S0168-8278(13)60898-3","article-title":"Successful HCV eradication due to antiviral therapy is associated with improved long term outcome of patients with chronic hepatitis C","volume":"58","author":"Rutter","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.10.017_b0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3748\/wjg.v17.i4.493","article-title":"Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin","volume":"17","author":"Trapero-Marugan","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.017_b0125","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0130","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/hep.22251","article-title":"Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus","volume":"47","author":"Veldt","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrendo.2011.183","article-title":"The worldwide epidemiology of type 2 diabetes mellitus\u2013present and future perspectives","volume":"8","author":"Chen","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2016.10.017_b0140","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0145","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0150","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.10.017_b0155","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.10.017_b0160","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0165","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-138-4-200302180-00008","article-title":"Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus","volume":"138","author":"Shiratori","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0175","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1478-3231.2006.01260.x","article-title":"Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma","volume":"26","author":"Akamatsu","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.10.017_b0180","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MEG.0b013e32831101b7","article-title":"Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy","volume":"21","author":"Sewell","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.10.017_b0190","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/jac\/dks269","article-title":"A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy","volume":"67","author":"Chang","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2016.10.017_b0195","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2169\/internalmedicine.47.1087","article-title":"Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients","volume":"47","author":"Hirakawa","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0200","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00535-004-1519-2","article-title":"Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon","volume":"40","author":"Ikeda","year":"2005","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.017_b0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1478-3231.2004.0956.x","article-title":"Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy","volume":"24","author":"Iwasaki","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.10.017_b0210","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/cncr.20537","article-title":"Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy","volume":"101","author":"Makiyama","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2016.10.017_b0215","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1440-1746.2005.03800.x","article-title":"Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy","volume":"20","author":"Tokita","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.10.017_b0220","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s00535-013-0921-z","article-title":"Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes","volume":"49","author":"Yamashita","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.017_b0225","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/hep.26087","article-title":"Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C","volume":"57","author":"Arase","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0230","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","author":"Asahina","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.017_b0235","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-146-9-200705010-00008","article-title":"Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study","volume":"146","author":"Ikeda","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.10.017_b0240","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1289\/ehp.0901388","article-title":"Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment","volume":"118","author":"Liu","year":"2010","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jhep.2016.10.017_b0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0676.2003.01804.x","article-title":"Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence","volume":"23","author":"Pessione","year":"2003","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.10.017_b0250","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1360-0443.2009.02521.x","article-title":"Alcohol-related cirrhosis\u2013early abstinence is a key factor in prognosis, even in the most severe cases","volume":"104","author":"Verrill","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2016.10.017_b0255","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.12185","article-title":"The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection","volume":"21","author":"Van der Meer","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.10.017_b0260","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11901-013-0195-1","article-title":"Natural history of HCV-induced liver disease","volume":"12","author":"Van der Meer","year":"2013","journal-title":"Curr Hepatitis Rep"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816305827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816305827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T21:12:59Z","timestamp":1657487579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816305827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0168827816305827"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.10.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}